Myopia-control Efficacy by Peripheral Defocus Lens (PDL)

Sponsor
Tianjin Eye Hospital (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT05373693
Collaborator
(none)
160
1
4
39
4.1

Study Details

Study Description

Brief Summary

The proposed study below aims to assess the effect of customized Bestivue PDL lenses on retinal image quality and myopia control. A total of 160 subjected would be enrolled in and randomized to allcoate into four groups. Visual acuity and image blur at various gaze directions and eccentricities on children fitted with +2 to 4 D power and single vision lenses would be measured to assess the short term effect of PDL lens. Axial length and cycloplegic objective refractive error would be measured to assess the Myopia-control Efficacy.

Condition or Disease Intervention/Treatment Phase
  • Device: Single vision lens
  • Device: +2D PDL
  • Device: +3D PDL
  • Device: +4D PDL
N/A

Detailed Description

The proposed study below aims to assess the short-term and long-term effect of customized Bestivue PDL lenses on retinal image quality and myopia control. To these ends, two stages of testing are planned. First, objective testing will be utilized to assess the effect of Bestivue PDL lenses on visual acuity and image blur at various gaze directions and eccentricities on 4- to 13-year-old children fitted with +2 to 4 D power and single vision lenses.In the second stage, the same children participants will wear either single or Bestvue PDL lenses with one of the four plus power designs for 2 years. Their corrected visual acuity, objective refractive error with dilation and axial length will be assessed for each eye every six months for two years. Outcomes of these studies should inform whether Bestivue PDL lenses are effective in myopia control while affording adequate visual comfort and performance.

Study Design

Study Type:
Interventional
Actual Enrollment :
160 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Prevention
Official Title:
Evaluation of Visual Performance and Myopia-control Efficacy Afforded by Bestivue Peripheral Defocus Lens (PDL)
Actual Study Start Date :
Jul 1, 2019
Anticipated Primary Completion Date :
Sep 30, 2022
Anticipated Study Completion Date :
Sep 30, 2022

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: Control group

The subjects are randomized to wear SV lens

Device: Single vision lens
Wear single vision lens

Experimental: experimental group +2D

The subjects are randomized to wear special designed lens with +2D Peripheral Defocus.

Device: +2D PDL
Wear Peripheral defocus lense with +2D

Experimental: experimental group +3D

The subjects are randomized to wear special designed lens with +3D Peripheral Defocus.

Device: +3D PDL
Wear Peripheral defocus lense with +3D

Experimental: experimental group +4D

The subjects are randomized to wear special designed lens with +4D Peripheral Defocus.

Device: +4D PDL
Wear Peripheral defocus lense with +4D

Outcome Measures

Primary Outcome Measures

  1. changes in cycloplegic objective spherical equivalent (SER) [baseline, 24 months]

    changes in cycloplegic objective spherical equivalent (SER) from baseline between four groups.

Secondary Outcome Measures

  1. changes in ocular axial length [baseline, 24 months]

    Changes in ocular axial length from baseline between four groups.

  2. visual performance [1 day]

    The visual acuity of peripheral between four groups.

Eligibility Criteria

Criteria

Ages Eligible for Study:
6 Years to 15 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • The subjects had spherical RE of -1.00 to -6.00 D

  • Astigmatism ≤ 4.00 D

  • Anisometropia ≤ 1.50 D\

  • Best corrected visual acuity (BCVA) equal to or better than logMAR 0.0 (20/20) in both eyes.

Exclusion Criteria:
  • Strabismus

  • Ocular limitations

  • Systemic abnormalities affecting vision and ocular motility.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Tianjin Eye Hospital Tianjin China 300020

Sponsors and Collaborators

  • Tianjin Eye Hospital

Investigators

  • Principal Investigator: Lihua Li, Tianjin Eye Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Tianjin Eye Hospital
ClinicalTrials.gov Identifier:
NCT05373693
Other Study ID Numbers:
  • TJYYLL-2018-04
First Posted:
May 13, 2022
Last Update Posted:
May 13, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 13, 2022